Return to content in this issue

 

Successful Desensitization to Isatuximab in a Patient With Refractory Multiple Myeloma and Indolent Systemic Mastocytosis. Reply to: Anaphylactic Shock due to Isatuximab and Successful Desensitization

Hutten EM1, Roeloffzen WWH2, Lambeck AJA3, van den Born- Bondt T4, Oude Elberink HNG1, van de Ven AAJM1,5

1Department of Internal Medicine, Division of Allergology, University Medical Center Groningen, Groningen, The
Netherlands
2Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands
3Department of Laboratory Medicine, University Medical Center Groningen, Groningen, The Netherlands
4Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands
5Department Rheumatology and Clinical Immunology, University Medical Center Groningen, The Netherlands

J Investig Allergol Clin Immunol 2024; Vol 34(3) : 214-216
doi: 10.18176/jiaci.0990

Key words: Anaphylaxis, Isatuximab, Desensitization, Systemic mastocytosis